Livedoid vasculitis - Vasculitis Livedoid
Vasculitis Livedoid (Livedoid vasculitis) jẹ arun aiṣan-ara onibaje ti a rii ni pataki ninu awọn ọdọ si awọn obinrin ti o jẹ agbalagba. Acronym kan ti a lo lati ṣe apejuwe awọn ẹya ara ẹrọ rẹ jẹ "Awọn ọgbẹ purpuric irora pẹlu apẹrẹ reticular ti awọn opin isalẹ" (PURPLE). O ni nkan ṣe pẹlu nọmba awọn arun, pẹlu haipatensonu iṣọn-ẹjẹ onibaje ati awọn varicosities.
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
O le wa pẹlu irora.
References
Livedoid vasculopathy jẹ ipo awọ to ṣọwọn ti o jẹ ifihan nipasẹ awọn ọgbẹ irora ti o ma pada wa ni awọn ẹsẹ isalẹ.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy jẹ arun awọ to ṣọwọn ti o fa awọn adaijina loorekoore lori awọn ẹsẹ isalẹ, ti o fi silẹ lẹhin awọn aleebu didan ti a mọ si atrophie blanche. Lakoko ti idi ti o daju ko ṣiyeju, o gbagbọ pe didi ẹjẹ ti o pọ si (hypercoagulability) jẹ ifosiwewe akọkọ, pẹlu igbona ti n ṣe ipa keji. Awọn nkan ti o ṣe idasi si didi pẹlu bi atẹle - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Ninu awọn biopsies, ipo naa fihan awọn didi ẹjẹ inu awọn ohun elo, nipọn ti awọn odi ọkọ, ati aleebu. Itọju jẹ ọna ti o ni ilọsiwaju pupọ ni idojukọ lori idilọwọ awọn didi ẹjẹ pẹlu awọn oogun bii awọn oogun egboogi-platelet, awọn tinrin ẹjẹ, ati itọju ailera fibrinolytic. Awọn oogun oriṣiriṣi le ṣee lo fun ipo awọ ara - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy jẹ ipo ti o ṣọwọn nibiti awọn egbo ba waye lori awọn ẹsẹ mejeeji. Ipilẹṣẹ ti awọn didi ẹjẹ ni awọn ohun elo ẹjẹ kekere ni a ro pe o fa nipasẹ didi ti o pọ si ati idinku idinku, pẹlu ibajẹ si awọ inu ọkọ. O wọpọ julọ ni awọn obinrin, paapaa laarin awọn ọjọ-ori 15 ati 50. Didi siga mimu duro, itọju awọn ọgbẹ, ati lilo awọn oogun bii awọn tinrin ẹjẹ ati awọn oogun antiplatelet ti munadoko.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
